Niklas Loman
Niklas Loman
Associate Professor Dept of Oncology Lund University Hospital
Verified email at
Cited by
Cited by
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies
A Antoniou, PDP Pharoah, S Narod, HA Risch, JE Eyfjord, JL Hopper, ...
The American Journal of Human Genetics 72 (5), 1117-1130, 2003
Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
A Tutt, M Robson, JE Garber, SM Domchek, MW Audeh, JN Weitzel, ...
The Lancet 376 (9737), 235-244, 2010
Gene-expression profiles in hereditary breast cancer
I Hedenfalk, D Duggan, Y Chen, M Radmacher, M Bittner, R Simon, ...
New England Journal of Medicine 344 (8), 539-548, 2001
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
B Kaufman, R Shapira-Frommer, RK Schmutzler, MW Audeh, ...
Journal of clinical oncology 33 (3), 244-250, 2014
Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
MW Audeh, J Carmichael, RT Penson, M Friedlander, B Powell, ...
The Lancet 376 (9737), 245-251, 2010
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ...
The Lancet Oncology 18 (12), 1688-1700, 2017
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer
TR Rebbeck, N Mitra, F Wan, OM Sinilnikova, S Healey, L McGuffog, ...
Jama 313 (13), 1347-1361, 2015
An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression
A Palazon, PA Tyrakis, D Macias, P Veliša, H Rundqvist, S Fitzpatrick, ...
Cancer cell 32 (5), 669-683. e5, 2017
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the generalá…
AC Antoniou, X Wang, ZS Fredericksen, L McGuffog, R Tarrell, ...
Nature genetics 42 (10), 885, 2010
Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer
N Loman, O Johannsson, U Kristoffersson, H Olsson, A Borg
Journal of the National Cancer Institute 93 (16), 1215-1223, 2001
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk
FJ Couch, X Wang, L McGuffog, A Lee, C Olswold, KB Kuchenbaecker, ...
PLoS genetics 9 (3), e1003212, 2013
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
SM Domchek, C Aghajanian, R Shapira-Frommer, RK Schmutzler, ...
Gynecologic oncology 140 (2), 199-203, 2016
Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors
M Laakso, N Loman, ┼ Borg, J Isola
Modern pathology 18 (10), 1321, 2005
Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics
G J÷nsson, J Staaf, J Vallon-Christersson, M RingnÚr, K Holm, C Hegardt, ...
Breast Cancer Research 12 (3), R42, 2010
Identification of new microRNAs in paired normal and tumor breast tissue suggests a dual role for the ERBB2/Her2 gene
H Persson, A Kvist, N Rego, J Staaf, J Vallon-Christersson, L Luts, ...
Cancer research 71 (1), 78-86, 2011
Molecular classification of familial non-BRCA1/BRCA2 breast cancer
I Hedenfalk, M RingnÚr, A Ben-Dor, Z Yakhini, Y Chen, G Chebil, R Ach, ...
Proceedings of the National Academy of Sciences 100 (5), 2532-2537, 2003
Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial
O Bjarnadottir, Q Romero, PO Bendahl, K Jirstr÷m, L RydÚn, N Loman, ...
Breast cancer research and treatment 138 (2), 499-508, 2013
Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer.
S Hňkansson, O Johannsson, U Johansson, G Sellberg, N Loman, ...
American journal of human genetics 60 (5), 1068, 1997
Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes
N Loman, O Johannsson, PO Bendahl, ┼ Borg, M Fern÷, H Olsson
Cancer 83 (2), 310-319, 1998
Identification of subtypes in human epidermal growth factor receptor 2–positive breast cancer reveals a gene signature prognostic of outcome
J Staaf, M RingnÚr, J Vallon-Christersson, G J÷nsson, PO Bendahl, ...
Journal of Clinical Oncology 28 (11), 1813-1820, 2010
The system can't perform the operation now. Try again later.
Articles 1–20